How big is Omega Therapeutics, Inc.?

As of Jun 18, Omega Therapeutics, Inc. has a market capitalization of 1.72 million, with net sales of 8.09 million and a net profit of -73.08 million over the last four quarters. Shareholder's funds total 58.02 million, and total assets are valued at 204.37 million.

As of Jun 18, Omega Therapeutics, Inc. has a market capitalization of 1.72 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 8.09 million, while the sum of net profit for the same period is -73.08 million.<BR><BR>As of Dec 23, the shareholder's funds amount to 58.02 million, and the total assets are valued at 204.37 million.

What does Omega Therapeutics, Inc. do?

Omega Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net loss of $16 million as of September 2024. The company has a market cap of $1.72 million and does not pay dividends.

Overview: <BR>Omega Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Million (Quarterly Results - Sep 2024) <BR>Most recent Net Profit: -16 Million (Quarterly Results - Sep 2024) <BR>Market-cap: USD 1.72 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.28 <BR>Return on Equity: -633.21% <BR>Price to Book: 0.15<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Omega Therapeutics, Inc.?

Is Omega Therapeutics, Inc. overvalued or undervalued?

As of November 8, 2022, Omega Therapeutics, Inc. is considered overvalued and rated as risky due to significant financial challenges, including a P/E ratio of NA from losses, a price to book value of 0.15, an EV to EBITDA ratio of 0.02, a ROE of -633.21%, and a year-to-date return of -96.67%, which contrasts unfavorably with its peers.

As of 8 November 2022, the valuation grade for Omega Therapeutics, Inc. moved from does not qualify to risky. The company is currently considered overvalued given its significant financial challenges, including a P/E ratio of NA due to losses, a price to book value of 0.15, and an EV to EBITDA ratio of 0.02. These metrics indicate a company struggling to generate positive returns, as evidenced by a ROE of -633.21%.<BR><BR>In comparison to its peers, Omega Therapeutics has a less favorable standing; for instance, Theseus Pharmaceuticals, Inc. is rated fair with a P/E of -3.1720, while Vaxart, Inc. is also risky with a P/E of -2.3400. The stark contrast in valuations highlights the challenges Omega faces in the market. Additionally, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -96.67%, reinforcing the notion that it is overvalued in its current state.

Is Omega Therapeutics, Inc. technically bullish or bearish?

As of July 14, 2025, Omega Therapeutics, Inc. shows a mildly bearish trend with daily moving averages and weekly Dow Theory indicating bearishness, despite a contrasting bullish monthly RSI, and has significantly underperformed the S&P 500 with a year-to-date return of -99.6%.

As of 14 July 2025, the technical trend for Omega Therapeutics, Inc. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a bearish trend and the weekly Dow Theory also signaling bearishness. The weekly RSI is bearish, contrasting with the monthly RSI which is bullish, indicating mixed signals across different time frames. Additionally, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -99.6% versus the S&P 500's 12.22%.